Arthur Moseley is the Director of the Proteomics and Metabolomics Core Facility for the School of Medicine at Duke University. In this position he is responsible for the development and application of technologies for open (unbiased) qualitative and quantitative UPLC-MS/MS proteomic analyses using high resolution, accurate mass tandem mass spectrometers coupled with ultra-performance nanoscale capillary liquid chromatographs, and for targeted protein and metabolite quantitation using UPLC-MS/MS with multiple reaction monitoring (MRM) on triple quadrupole mass spectrometers.
The Proteomics and Metabolomics Core Facility has the capability for support a diverse range of research projects, from studies in Basic Sciences Departments through support of clinical trials for Clinical Sciences Departments. The clinical support has included biomarker discovery in studies in the areas of oncology, immunology, and infectious disease. Prior to his position at Duke University, he managed mass spectrometry laboratories at GSK for sixteen years, and for the last six years of these years he lead a transnational laboratory (US/UK) dedicated to proteomic biomarker discovery. Dr. Moseley received his MS in Physical Chemistry from North Carolina State University, and his PhD in Analytical Chemistry from the University of North Carolina at Chapel Hill. His dissertation, under the direction of Professor Jim Jorgenson, addressed the coupling of nanoscale separation with tandem mass spectrometry for the analysis of peptides and proteins.